Advertisement
Coronavirus pandemic
WorldEurope

Britain is first to approve Merck’s Covid-19 pill molnupiravir

  • The country’s drug regulator recommended molnupiravir be used within five days of the onset of symptoms
  • Health minister Sajid Javid said the government would set out plans to deploy the drug to patients through a national study as soon as possible

Reading Time:2 minutes
Why you can trust SCMP
In October, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir. Photo: Reuters
Reuters
Britain on Thursday became the first country in the world to approve a potentially game-changing Covid-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic.
Advertisement
The Medicines and Healthcare products Regulatory Agency (MHRA) recommended the drug, molnupiravir, be used as soon as possible following a positive Covid-19 test and within five days of the onset of symptoms.

This is the first oral antiviral treatment for Covid-19 to get approved, with the green light coming ahead of potential US regulatory clearance. US advisers will meet this month to vote on whether molnupiravir should be authorised.

The drug, to be branded Lagevrio in Britain, has been closely watched since data last month showed it could halve the chances of dying or being hospitalised for those most at risk of developing severe Covid-19 when given early in the illness.

The British government and the country’s National Health Service will confirm how the treatment will be deployed to patients in due course.

Advertisement

Last month, Britain agreed a deal with Merck to secure 480,000 courses of molnupiravir.

Advertisement